
SOPH Stock Forecast & Price Target
SOPH Analyst Ratings
Bulls say
Sophia Genetics is a rapidly growing healthcare technology company with a strong presence in the United States and a global customer base. They have a proven track record of revenue growth and customer acquisition, supported by their innovative use of artificial intelligence in medical data analysis. The company's strategic partnerships and investments in their data management system demonstrate their commitment to continuous improvement and expansion. While facing challenges in their biopharma division, SOPH is expected to reach profitability in the medium term, making them an attractive stock investment opportunity.
Bears say
Sophia Genetics is expanding its revenue through its relationship with the Mayo Clinic and signing 60 customers for its MSK ACCESS application, but has not yet generated significant revenue from these customers. Additionally, only a small percentage of customers are utilizing multiple applications, raising concerns about SOPH's land and expand model. Furthermore, while the new exome product is promising, it is unclear how quickly SOPH will see revenue generation from this product given the slow adoption of their other offerings.
This aggregate rating is based on analysts' research of Sophia Genetics SA and is not a guaranteed prediction by Public.com or investment advice.
SOPH Analyst Forecast & Price Prediction
Start investing in SOPH
Order type
Buy in
Order amount
Est. shares
0 shares